NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Clinical Trials
15 trialsNCT02362594 2026-03-05
MK-3475-054
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT02360579 2025-12-09
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Completed
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT04099251 2025-08-27
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03599713 2025-08-05
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
Phase 2 Completed
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT02388906 2025-04-24
CheckMate 238
Bristol-Myers Squibb
Phase 3 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT03665597 2025-02-10
KEYNOTE-555
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03553836 2024-11-29
KEYNOTE-716
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01728805 2024-04-25
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT01682083 2023-08-30
COMBI-AD
Novartis
Phase 3 Completed
NCT02267603 2023-07-05
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed